BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32767949)

  • 1. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
    Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
    Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of a Newly Synthesized Ferrocene Derivative against MCF-7 Breast Cancer Cells and Spheroid Stem Cells through ROS Production and Inhibition of JAK2/STAT3 Signaling Pathway.
    Nourbakhsh M; Farzaneh S; Taghikhani A; Zarghi A; Noori S
    Anticancer Agents Med Chem; 2020; 20(7):875-886. PubMed ID: 31893999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
    Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
    Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Zhang ZL; Jiang QC; Wang SR
    Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Antiproliferative Activity of Ferrocene Derivatives against Drug- Resistant Cancer Cell Lines: A Mini Review.
    Li L; Ma L; Sun J
    Curr Top Med Chem; 2021; 21(19):1756-1772. PubMed ID: 34323188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucuna pruriens (L.) DC chemo sensitize human breast cancer cells via downregulation of prolactin-mediated JAK2/STAT5A signaling.
    Sinha S; Sharma S; Vora J; Shah H; Srivastava A; Shrivastava N
    J Ethnopharmacol; 2018 May; 217():23-35. PubMed ID: 29427634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentadecanoic Acid, an Odd-Chain Fatty Acid, Suppresses the Stemness of MCF-7/SC Human Breast Cancer Stem-Like Cells through JAK2/STAT3 Signaling.
    To NB; Nguyen YT; Moon JY; Ediriweera MK; Cho SK
    Nutrients; 2020 Jun; 12(6):. PubMed ID: 32503225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
    Zhang T; Jiang B; Zou ST; Liu F; Hua D
    World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naringenin enhances anti-proliferation effect of 1-ferrocenyl-3-(4-methylsulfonylphenyl) propen-1-one on two different cells via targeting calmodulin signaling pathway.
    Rajabi S; Noori S; Ashrafi MR; Movahed MA; Farzaneh S; Zarghi A
    Mol Biol Rep; 2022 Feb; 49(2):1027-1036. PubMed ID: 35028851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells.
    Seo HS; Ku JM; Lee HJ; Woo JK; Cheon C; Kim M; Jang BH; Shin YC; Ko SG
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28864784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
    Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
    Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway.
    Li H; Lu Y; Pang Y; Li M; Cheng X; Chen J
    Biomed Pharmacother; 2017 Feb; 86():324-333. PubMed ID: 28011380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
    Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
    Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway.
    Maashi MS; Al-Mualm M; Al-Awsi GRL; Opulencia MJC; Al-Gazally ME; Abdullaev B; Abdelbasset WK; Ansari MJ; Jalil AT; Alsaikhan F; Shalaby MN; Mustafa YF
    Mol Biol Rep; 2022 Sep; 49(9):8777-8784. PubMed ID: 35804214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer.
    Gao C; Yuan X; Jiang Z; Gan D; Ding L; Sun Y; Zhou J; Xu L; Liu Y; Wang G
    Breast Cancer Res Treat; 2019 Jul; 176(2):291-301. PubMed ID: 31006103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway.
    Yao X; Zhu F; Zhao Z; Liu C; Luo L; Yin Z
    J Cell Biochem; 2011 Oct; 112(10):2837-49. PubMed ID: 21608020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
    Yi D; Xu L; Wang R; Lu X; Sang J
    Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
    Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2.
    Huang H; Niu J; Wang F; Hu L; Yu Q
    Invest New Drugs; 2019 Jun; 37(3):452-460. PubMed ID: 30073465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.